Journal of Clinical Immunology & Immunotherapy Category: Clinical Type: Research Article

Rubella Specific IgG and IgM Antibodies among Infants before Rubella Vaccination in Dar es Salaam, Tanzania: A Cross-Sectional Study

Mtebe V Majigo#1*, Mariam Ibrahim1,#2, Joel Manyahi1, Fausta Mosha3, Marcelina Mashurano1, Fred S Mhalu1 and4
1 Department Of Microbiology And Immunology, Muhimbili University Of Health And Allied Sciences, Dar Es Salaam, Tanzania, United Republic Of
2 Tanzania Industrial Research And Development Organization, Dar Es Salaam, Tanzania, United Republic Of
3 Ministry Of Health Community Development Gender Elderly And Children, Tanzania, United Republic Of
4 Department Of Microbiology And Immunology, St Joseph University In Tanzania, College Of Health And Allied Sciences, Dar Es Salaam, Tanzania, United Republic Of

*Corresponding Author(s):
Mtebe V Majigo#
Department Of Microbiology And Immunology, Muhimbili University Of Health And Allied Sciences, Dar Es Salaam, Tanzania, United Republic Of
Tel:+255 754 265561,
Email:mmajigo@gmail.com,
# Equal contribution

Received Date: Mar 17, 2020
Accepted Date: Apr 17, 2020
Published Date: Apr 24, 2020

Abstract

Background: Prevention of Rubella virus infection using rubella vaccine has been widely used in high-income countries contributing to the declining of congenital rubella syndrome. Before introduction of rubella vaccine in Tanzania October 2014, status of rubella specific antibodies in the infant was limited. This study was conducted to assess the rubella specific IgG and IgM antibodies among infants before receiving the vaccine.

Methods: A cross-sectional study was conducted in March 2015, at Ilala Municipality Dar es Salaam Tanzania among infants aged 9 months. A structured questionnaire was used for data collection. Dried blood spots were collected and tested for the presence of Rubella specific IgG and IgM antibodies using enzyme-linked immunosorbent Assay. The sero positivity of rubella antibodies was expressed as proportions.

Results: A total of 150 infants were recruited in the study, the majority 79 (52.7%) were males. A total of 104 (69.3%) were positive to IgG antibodies while 7 (4.7%) were positive IgM antibodies. Around 21 (20. 2%) of infants had a strong immunity to rubella with IgG titres ≥ 15 IU/ml. There were a significantly different proportion of IgG antibodies with infant location

Conclusion: There is substantial preclinical rubella infection in Dar es Salaam, before the age of rubella vaccination.

Abbreviations

CRS: Congenital Rubella Syndrome

DBS: Dry Blood Spot

ELISA: Enzyme-Linked Immunosorbent Assay

IgG: Immunoglobulin G

IgM: Immunoglobulin M

MUHAS: Muhimbili University of Health and Allied Sciences

OD: Optical Density

RCV: Rubella Contained Vaccine

Keywords

Rubella; Infants; IgM; IgG; Antibodies

INTRODUCTION

Rubella infection is an acute, mild viral disease mainly affecting susceptible children and young adults worldwide. In most cases, the disease is self-limiting but may lead to congenital rubella infection with complications of Congenital Rubella Syndrome (CRS) [1,2]. When infection occurs in the first trimester, 90% of infants may present with CRS [3]. Rubella infection in some African countries is common among under-five years old children, suggesting the possibility of infection at a younger age [4,5]. Some studies have reported Rubella virus-specific IgM and IgG seroprevalence to increase with the increase of age [4,5]. A study done in Mwanza Tanzania reported seroprevalence of rubella specific IgG of 92.6%, among pregnant women signifying natural immunity [6]. 

In rubella, passive immunity results from the acquisition of specific IgG antibodies from a previously infected pregnant mother across the placenta or through breastfeeding which may persist for 4-6 months after birth [7]. Following rubella infection or immunization, IgM antibodies develop within 2 weeks and do not persist beyond 6 weeks. On the other hand, specific IgG antibodies develop and usually persist for life [8]. 

Prevention of Rubella virus infection using Rubella Containing Vaccine (RCV) has been widely used in high-income countries with a considerable decline of CRS [9-12]. The main aim of vaccination is to ensure women of childbearing age have protective immunity to Rubella virus. There is some variation among countries in terms of the concentration of IgG antibodies considered to be protective. However, the presence of rubella IgG antibodies ≥ 10 IU/ml is commonly considered to provide evidence of protection [13]. 

There was no routine rubella vaccination in Tanzania before October 2014, when the rubella vaccine was introduced country-wide. The status of rubella specific antibodies in infant prior vaccination was not known. This study was conducted to assess the seroprevalence of rubella specific antibodies among infants at 9 months of age just before receiving routine immunization with RCV.

MATERIALS AND METHODS

Study design, setting, and population

A descriptive cross-sectional study was conducted in March 2015 in Dar es Salaam, the largest city in Tanzania with an estimated population of around six million inhabitants. The study was conducted at three reproductive and child health clinics located at Bugruni, Ukonga and Tabata suburbs in Ilala District. The study population was infants at nine months of age attending reproductive and child health clinics clinic for routine immunization with RCV. The sample size was estimated using Kish Leslie formula at 95 % confidence interval (CI) considering 10% seroprevalence of rubella specific IgM antibody among under five in Mwanza Tanzania [14] and 5% margin of error.

Data and specimen collection

A structured questionnaire for socio-demographic information of each infant and mother pair was completed by the clinic Nurse. Dried Blood Spot (DBS) specimens were collected from a heel or finger prick by sterile single-use self-launching pediatric lancet onto each of the four 13-mm diameter circles on Schleicher & Schuell #903 filter paper. The DBS samples were dried on racks at room temperature, wrapped in clean wax paper and then placed in plastic zip-lock bags. Up to 15 wrapped filter paper samples were placed in a single bag, along with sachets of 1g silica gel desiccant (Minipax sorbent Packets; Technologies, Ink) then transported to the Immunology laboratory at Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam for storage at -20οC until the time of testing.

Laboratory investigations and analysis

Rubella specific IgG and IgM antibodies were determined using commercially available enzyme-linked immunosorbent assay (ELISA) (virion/serion D-97076 W?rzburg, Germany) according to the manufacturer's instructions. Briefly, the blood spots were punctured and put into microplate wells for overnight elution using sample buffer. The materials were pre-treated with rheumatoid factor-absorbent before IgM detection to remove the possibility of false positives.

The standard curve for both IgG and IgM established by the manufacturer was supplied with the ELISA kit having optical density (OD) readings of calibrators on the vertical (Y) axis and respective concentration in IU/ml on the horizontal (X) axis. The concentration of Rubella Specific IgG and IgM antibodies in a sample was determined by comparison of OD of each sample to the concentration of the calibrators of the standard curve. The intra-assay variations of OD were corrected by multiplying with the correction factor, calculated as the ratio of OD reference value to mean of standards of each reading plate according to the manufacturer’s instructions.

Data analysis

Data were entered in excel software and analysed using Statistical Package for Social Sciences version 20.0. Continuous variables are presented as means and Standard deviation and categorical variables as numbers and proportions. Group differences were examined by using Student’s t-test for continuous variables and chi2 tests for categorical variables. The antibody titre ≥10 IU/ml specific for rubella were considered positive and infants with IgG antibody levels of  ≥10 IU/ml were considered to have rubella virus seroprotective titres [15].

RESULTS

Social Demographic and clinical characteristics

The study recruited 150, the majority 79 (52.7%) were males and 71(47.3%) were residents of Buguruni. The mean weight of infants was 8.29 ± 2.24 kg, great count (51.3%) weighted the mean. Only 6 (4.0%) reported a history of hospital admission (Table 1). No infant had neither history of blood transfusion nor clinical features associated with rubella infections, including CRS.A large proportion of the infants’ mothers reported being married 112 (86.3%), unemployed 97(64.7%) and lower education level. The HIV serostatus was revealed in 140 of mothers, among them, 9 (6.4%) were HIV seropositive (Table 1). 


Characteristic

Frequencies

Percent (%)

Sex of Infant

 

 

Male

79

52.7

Female

71

47.3

Location

 

 

Buguruni

73

48.7

Ukonga

30

20.0

Tabata

47

31.3

Weight of Infant (Kg)

 

 

Mean ± SD

8.29 ±1.25

 

Below mean (0 - 8.2)

77

51.3

Above mean (>8.29)

73

48.7

History of Hospitalization

 

 

No

144

96.0

Yes

6

4.0

Mothers' marital status

 

 

Married

125

83.3

Not married

25

16.7

Mothers’ Education Level

 

Lower Level

104

69.3

Higher Level

46

30.9

Mothers’ Occupation

 

 

Employed/Business

53

35.3

Unemployed

97

64.7

HIV-Mothers(n=140)

 

 

Negative

131

93.6

Positive

9

6.4

 Table 1: Characteristics of infants at nine months old and their mothers attending reproductive and child health clinic in Dar es Salaam, Tanzania.

Seroprevalence of rubella-specific IgG and IgM antibodies

A total of 104 (69.3%), 46(30.7%) and 7(4.7%) were found to be immune (IgG positive), non-immune (IgG-- negative and recently infection (IgM positive) respectively. Out of the 104 found immune with IgG titres ≥ 10 IU/ml, 21(20.2 %) had strong immunity with IgG titres ≥ 15 IU/ml (Table 2). The mean IgG titer was 11.47 ± 5.82; the majority of infants (52%) had IgG antibodies titres below the mean. 

Results of sero-markers

Frequency (%)

IgG antibodies

 

Positive

104 (69.3)

Negative

46 (30.7)

IgM antibodies

 

Positive

7 (4.7)

Negative

143(95.3)

IgG Titres (IU/ml)

 

Mean ± SE

11.47± 5.82

<10

46 (30.7)

10 - <15

83 (55.3)

≥ 15

21 (14.0)

Table 2: Rubella specific IgG and IgM among nine months aged infants before vaccination in Ilala Municipality, Dar es Salaam, Tanzania.

Characteristics of participants and Rubella Specific IgG antibodies

The proportion of positive IgG antibodies were significantly higher among infants from Tabata (89.4%) and Ukonga (80.0%) than Buguruni (52.1%) (p<0.001). The proportion differences of IgG antibodies observed among infant’s sex mean weight, history of hospitalization and mothers’ characteristics were not statistically significant (>0.05) (Table 3).

Variable

IgG antibodies

P-value

Positive

N (%)

Negative

N (%)

sex

 

 

 

Male

57 (72.2)

22 (27.8)

0.430

Female

47 (66.2)

24 (33.8)

0.415

Mean weight

8.35 ± 1.2

8.16 ± 1.3

 

Location

 

 

 

Bugruni

38 (52.1)

35 (47.9)

< 0.001

Ukonga

24 (80.0)

6 (20.0)

 

Tabata

42 (89.4)

5 (10.6)

 

History of Hospitalization

 

 

 

No

99 (68.8)

45 (31.2)

0.448

Yes

5 (83.3)

1 (16.7)

 

Mothers’ education level

 

 

 

Low

35 (74.5)

12 (25.5)

0.357

High

69 (67.0)

34 (33.0)

 

Mothers’ marital status

 

 

 

Not married

20 (80.0)

5 (20.0)

0.205

Married

84 (67.2

41 (32.8)

 

Mothers’ occupation

 

 

 

Unemployed

69 (71.1)

28 (28.9)

0.518

Employed/Business

35 (66.0)

18 (34.0)

 

Mothers’ HIV status

 

 

 

Negative

89 (67.9)

42 (32.1)

0.188

Positive

8 (88.9)

1 (11.1)

 

 Table 3: Descriptive characteristic of participants and the status of rubella specific IgG antibodies.

DISCUSSION

To the best of our knowledge, this is the first study in Tanzania to investigate the status of rubella IgM and IgG antibodies at the age of nine months of unvaccinated infants. Determination of IgG and IgM antibodies helps to reveal the proportion of infants with a protective level of immunity, susceptible to infection and those with recent infection. This study observed over two-third of infants having a protective level of natural immunity at nine months of age. Also, the study revealed the 5% of infants with evidence of recent exposure to rubella infection based on rubella specific IgM antibodies. 

Existence of rubella IgM antibodies is evidence of natural infection; therefore, our findings suggested that some infants get Rubella virus infection before nine months, the age set for rubella vaccination in Tanzania. However, susceptibility to rubella virus infection before the age of vaccination is associated with the location of residence. We observed that infants from Bugruni were more susceptible than the other two locations based on a non-protective level of immunity, with a risk difference of 28-37%. The IgM seroprevalence found in this study is higher compared to findings from Sudan, where at 12 months of age, 2% of children had rubella IgM antibodies [1]. Likewise, our findings are comparable to the study in Mwanza, Tanzania among children aged 0-5 years, which reported an increase in rubella specific IgM seroprevalence significantly as the age increased [5]. 

The finding in this study that over two-third of infants were positive to rubella specific IgG antibodies at 9 months, suggests early sub-clinical rubella infection after birth which builds observed high level of natural immunity. Although passively transmitted maternal antibodies to rubella may contribute, the previous report indicates that approximately 5% of infants may still have maternal antibodies at 9 to 12 months [16]. The absence of clinical features of rubella infection among participants in this study increase evidence for the occurrence of subclinical infection among infants before nine months [2]. 

Routine rubella vaccination was introduced in Tanzania in 2014 for infants at nine months in a combination with Measles vaccine. The findings in our study that over two-third of infants had protective immunity is an indication that at nine-month might not be the appropriate age for the rubella vaccine in our setting. The age for rubella vaccination may be different depending on local established data of rubella natural immunity [17]. in most developed countries, RCV is given to children at 12 months of age because passively acquired maternal antibodies have usually disappeared by that age [8]. Our finding of a significant level of serological markers of rubella infection at the age of 9 months before vaccination is not surprising as rubella infection has been reported being common in many resource-constrained countries without routine vaccination where outbreaks may occur without clinical recognition [2,13]. In most cases, the disease is self-limiting and rarely causes complications in children. 

With this evidence of early infection before the age of rubella vaccination in our setting, there is still an increased risk of transmission of the virus to susceptible pregnant women in the community that increases the chance of CRS. These findings warrant more investigation to determine the appropriate age for initiating Rubella vaccination in our setting. 

This study was conducted at a reproductive and child health clinic. Normally, sick infants attend hospitals instead of reproductive and child health clinics. There is a possibility of missing infants with acute rubella infection at nine months old.

CONCLUSION

There is serological evidence of substantial preclinical rubella infection with two-third of infants having natural immunity at nine months of age. The findings warrant more investigations to determine the most appropriate age for giving the first rubella vaccination.

DECLARATIONS

Ethics approval and consent to participate

Ethical clearance was obtained from the Senate Research and Publications Committee of the Muhimbili University of Health and Allied Sciences in Dar es Salaam, Tanzania. Administrative permission for the study was granted by the Ilala Municipal Health authorities in Dar es Salaam city. Written informed consent for infants’ participation in the study was obtained from parents or guardians before enrolment into the study.

Availability of data and material

All relevant data generated and analyzed during this study are available from the corresponding author on reasonable request.

Funding

This study received financial support from East Africa Public Health Laboratory Networking Project (EAPHLNP) and we declare that the funder did not participate in the design of the study, data collection, analysis, and interpretation, and in the manuscript preparation.

Authors’ contribution

MI, JM, FM, and FSM participated in the conception and designing of the study. MI participated in data collection while MI and MM performed the serological tests. MI, FM, MM, FSM analyzed, interpreted the data and participated in the writing of the manuscript. All authors read and approved the final version of the manuscript.

ACKNOWLEDGEMENT

We acknowledge the cooperation of the mothers of the study infants, management of the Reproductive and Child Health Clinics in the Ilala municipality and in particular the nurses at clinics where the study was done. We are grateful to Mr. Kahongolela from the Ilala Municipality, Dar es Salaam City for his assistance and guidance.

REFERENCES

  1. Adam O, Ali AK, Hubschen JM, Muller CP (2014) Identification of congenital rubella syndrome in Sudan. BMC Infect Dis 14: 305.
  2. Junaid SA, Akpan KJ, Olabode AO (2011) Sero-survey of rubella IgM antibodies among children in Jos, Nigeria. Virol J 8: 244.
  3. Miller E, Waight P, Gay N, Ramsay M, Vurdien J, et al. (1997) The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: Fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Commun Dis Rep CDR Rev 7: R26-32.
  4. Manirakiza A, Kipela JM, Sosler S, Daba RM, Gouandjika Vasilache I (2011) Seroprevalence of measles and natural rubella antibodies among children in Bangui, Central African Republic. BMC Public Health 11: 327.
  5. Mirambo MM, Aboud S, Mushi MF, Seugendo M, Majigo M, et al. (2016) Serological evidence of acute rubella infection among under-fives in Mwanza: A threat to increasing rates of congenital rubella syndrome in Tanzania. Ital J Pediatr 42: 54.
  6. Mwambe B, Mirambo MM, Mshana SE, Massinde AN, Kidenya BR, et al. (2014) Sero-positivity rate of rubella and associated factors among pregnant women attending antenatal care in Mwanza, Tanzania. BMC Pregnancy Childbirth 14: 95.
  7. Waaijenborg S, Hahne SJ, Mollema L, Smits GP, Berbers GA, et al. (2013) Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis 208: 10-16.
  8. Vauloup Fellous C, Grangeot Keros L (2007) Humoral immune response after primary rubella virus infection and after vaccination. Clin Vaccine Immunol 14: 644-647.
  9. Davidkin I, Peltola H, Leinikki P (2004) Epidemiology of rubella in Finland. Euro Surveill 9: 13-14.
  10. de Haas R, van den Hof S, Berbers GA, de Melker HE, Spaendonck MA (1999) Prevalence of antibodies against rubella virus in The Netherlands 9 years after changing from selective to mass vaccination. Epidemiol Infect 123: 263-270.
  11. Schluter WW, Reef SE, Redd SC, Dykewicz CA (1998) Changing epidemiology of congenital rubella syndrome in the United States. J Infect Dis 178: 636-641.
  12. Tookey P (2004) Rubella in England, Scotland and Wales. Euro Surveill 9: 21-23.
  13. Best JM, Castillo Solorzano C, Spika JS, Icenogle J, Glasser JW, et al. (2005) Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee On Research Related To Measles and Rubella Vaccines and Vaccination, June 2004. J Infect Dis 192: 1890-1897.
  14. Mirambo MM, Aboud S, Groß U, Majigo M, Mushi MF, et al. (2017) Rubella seromarkers and determinants of infection among tanzanian children and adolescents in pre vaccination Era: Are we in the right track? International Journal of Preventive medicine 8: 3.
  15. Skendzel LP (1996) Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 106: 170-174.
  16. Nicoara C, Trachsel D, Germann D, Matter L (1999) Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses. Clinical and diagnostic laboratory immunology 6: 868-871.
  17. WHO (2000) WHO Position Paper on Rubella Vaccines. Weekly Epidemiological Record 75: 161-172.

Citation: Ibrahim M, Majigo MV, Manyahi J, Mosha F, Mashurano M, et al. (2020) Rubella Specific IgG and IgM Antibodies among Infants before Rubella Vaccination in Dar es Salaam, Tanzania. A Cross-Sectional Study. J Clin Immunol Immunother 6: 018.

Copyright: © 2020  Mtebe V Majigo#, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

© 2021, Copyrights Herald Scholarly Open Access. All Rights Reserved!